- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ZHAOKE OPHTH-B Guangzhou Nansha Production Base Obtains Australian GMP Certification | 1 | AASTOCKS | ||
| Di | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ZHAOKE OPHTHALMOLOGY'S MANUFACTURING FACILITY OBTAINS GMP CERTIFICATION FROM THE THERAPEUTIC GOODS ADMINISTRATION ... | 1 | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 22.10. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 20.10. | ZHAOKE OPHTH-B (06622): (REVISED) NEXT DAY DISCLOSURE RETURN (AMENDMENT FOR THE RETURN ON 16 OCTOBER NOVEMBER 2026) | 1 | HKEx | ||
| 20.10. | ZHAOKE OPHTH-B (06622): (REVISED) NEXT DAY DISCLOSURE RETURN (AMENDMENT FOR THE RETURN ON 15 OCTOBER NOVEMBER 2026) | 1 | HKEx | ||
| 15.10. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): 2026 INTERIM REPORT | - | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 04.09. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - CARBACHOL AND BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION (YUVEZZI) MET THE PRIMARY ENDPOINT IN THE PHASE ... | - | HKEx | ||
| 28.08. | ZHAOKE OPHTH-B (06622): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 17.08. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
| 12.08. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING AN EXCLUSIVE DISTRIBUTION AND PROMOTION AGREEMENT WITH PHARMENTUM BIOPHARMA TO COMMERCIALIZE ... | 1 | HKEx | ||
| 20.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INNOVATIVE PRESBYOPIA DRUG YUVEZZI APPROVED BY THE PHARMACEUTICAL ADMINISTRATION BUREAU OF THE GOVERNMENT ... | 1 | HKEx | ||
| 13.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERED INTO A DEFINITIVE AGREEMENT FOR THE ACQUISITION OF THE GLOBAL RIGHTS TO NVK002 (ATROPINE SULFATE ... | - | HKEx | ||
| 09.07. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 07.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INNOVATIVE PRESBYOPIA DRUG YUVEZZI APPROVED FOR USE AT BOAO SUPER HOSPITAL AS A CLINICALLY URGENT IMPORTED ... | 1 | HKEx | ||
| 30.06. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 30.06. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN(RESUBMISSION) | 2 | HKEx | ||
| 23.06. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | - | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | -0,11 % | EQT lässt für Qiagen 9,6 Milliarden Euro springen | Der schwedische Private-Equity-Investor EQT übernimmt den europäische Molekulardiagnostik-Spezialisten Qiagen. Mit 9,6 Mrd. Euro ist die Transaktion eine der größten Übernahmen im europäischen Gesundheitssektor... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | -0,04 % | Kymera Therapeutics: Brookline Capital hebt Kursziel nach Risikoreduzierung an | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | +0,12 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| TANGO THERAPEUTICS | 22,510 | -0,09 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für 4D Molecular Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 31,980 | +0,03 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen |
ZHAOKE OPHTHALMOLOGY LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,60 % bei einem Aktienkurs von 0,214 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHAOKE OPHTHALMOLOGY LTD finden Sie auf Wallstreet Online.